Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY21 results · Apr–Jun 2020
Lincoln Pharmaceuticals reported revenue from operations of ₹101.03 crore (up 6.8% from Q1 FY20) and net profit of ₹14.99 crore (up 23.2% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 101.03 | 94.59 | +6.8% | 75.26 | +34.2% |
| Other income | 1.97 | 1.58 | +25.0% | 5.31 | −62.8% |
| Total income | 103.01 | 96.17 | +7.1% | 80.57 | +27.8% |
| Profit before tax | 20.67 | 17.00 | +21.6% | 11.38 | +81.6% |
| Net profit for the period | 14.99 | 12.16 | +23.2% | 9.23 | +62.4% |
| EPS, basic (₹) | 7.50 | 6.08 | +23.4% | 4.62 | +62.3% |
| Net margin (%) | 14.8 | 12.9 | 12.3 |
Standalone
- Filed with BSE
- 20 Aug 2020, 14:57 IST
- Board meeting
- 20 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE